Secretive, $1.6 billion liquid biopsy player Grail files IPO, revealing 2021 commercial plans

Secretive, $1.6 billion liquid biopsy player Grail files IPO, revealing 2021 commercial plans

Source: 
Endpoints
snippet: 

The hunt for the Grail just got a lot easier. In fact, in a few weeks you’ll likely be able to pick up a portion of it on Robin Hood, no coconut horses required.

Grail, the monstrously backed liquid biopsy biotech, has filed for an IPO.